HP
NBIX icon

Havemeyer Place’s Neurocrine Biosciences NBIX Stock Holding History

Havemeyer Place’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
7,410
-1,586
-18% -$235K 0.12% 268
2026
Q1 		$1.19M Buy
8,996
+6,998
+350% +$929K 0.14% 279
2025
Q4 		$283K Buy
+1,998
New +$289K 0.06% 396

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Havemeyer Place's NBIX Position: Q2 2026 in Review

Havemeyer Place reduced its Neurocrine Biosciences (NBIX) stake by 18% in Q2 2026, selling an estimated $235K and leaving 7,410 shares worth $1.25M. The position accounts for 0.12% of the portfolio, ranked #268.

Havemeyer Place first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Havemeyer Place held 7,410 shares of Neurocrine Biosciences worth $1.25M as of Q2 2026.
  • Havemeyer Place sold 1,586 Neurocrine Biosciences shares in Q2 2026, an estimated $235K.
  • Neurocrine Biosciences made up 0.12% of Havemeyer Place's portfolio in Q2 2026, its #268 holding.
  • Havemeyer Place first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.